Pasar al contenido principal

CARACTERIZACION FUNCIONAL DE LA REGULACION DE LA INMUNIDAD INNATA Y ADAPTATIVA POR LAS CELULAS DENDRITICAS

BES-2017-079717

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos Predoctorales
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mitochondrial complex I activity promotes antigen cross-presentation in dendritic cells

  • Khouili, Sofía C
  • Priego, Elena
  • Heras-Murillo, Ignacio
  • Dunphy, Gillian
  • Mastrangelo, Annalaura
  • Martínez-Cano, Sarai
  • Nuñez, Vanessa
  • Rodrigo-Tapias, Manuel
  • Belinchón-García, Adrián
  • Garaude, Johan
  • Iborra, Salvador
  • Chandel, Navdeep S
  • González-Rodríguez, Patricia
  • Enamorado, Michel
  • Sancho, David
[Data, Code, and Materials Availability] Sequencing data have been deposited in GEO under accession number GSE325287. Metabolomics data have been deposited in Metabolomics Workbench under accession number ST004768. Tabulated data underlying the figures are provided in data file S1, and uncropped immunoblots are provided in data file S2. All other data needed to support the conclusions of the paper are present in the paper or the Supplementary Materials. No custom code was generated. All materials are commercially available as described in Materials and Methods., Mitochondrial metabolism modulates immune cell signaling, yet how individual electron transport chain complexes fine-tune dendritic cell (DC) function remains unclear. Here, we identify mitochondrial complex I (CI) as a critical metabolic checkpoint controlling antigen cross-presentation by DCs in mice. Deficiency of the CI subunit NDUFS4 in DCs led to the formation of a nonfunctional CI subcomplex, resulting in mildly impaired mitochondrial respiration without triggering a compensatory glycolytic shift. NDUFS4 deficiency limited endosomal escape of internalized antigens, thereby impairing antigen cross-presentation while largely preserving direct presentation. CI dysfunction lowered the NAD+/NADH ratio, concomitant with decreased ATP levels, and diminished neutral lipid storage and lipid peroxidation. Restoration of the NAD+/NADH ratio rescued cross-presentation in NDUFS4-deficient DCs. NDUFS2-deficient DCs showed similar defects in cross-presentation, which were also rescued by rebalancing the NAD+/NADH ratio. Together, these findings reveal a link between mitochondrial CI integrity, NAD+-driven redox metabolism, and antigen cross-presentation., [Editor's summary] Cross-presentation of extracellular antigens by dendritic cells (DCs) is a specialized function critical for eliciting CD8 T cell responses against viral and tumor antigens. Khouili et al. show that mitochondrial complex I (CI) activity supports antigen endosomal escape and promotes efficient cross-presentation by conventional type 1 DCs (cDC1s). CI activity selectively in cDC1s was also necessary for optimal cross-priming of CD8 T cell responses during viral infection and tumor challenge. Loss of the CI subunit NDUFS4 or NDUFS2 disrupted DC redox homeostasis, whereas restoration of the NAD+/NADH ratio was sufficient to rescue cross-presentation capacity. These findings identify mitochondrial redox metabolism as a key regulator of antigen cross-presentation in DCs. —Claire Olingy, E.P. was funded by Contratos Predoctorales para la Formación de Doctores 2017 (Referencia: BES-2017-079717). Metabolomics Workbench (68) is supported by NIH grants U2C-DK119886 and OT2-OD030544. Work in the D.S. laboratory is funded by the CNIC; by Ministerio de Ciencia, Innovación y Universidades (MICIU) PID2022-137712OB-I00, PDC2025-165319-I00, CPP2022-009762, and CPP2024-011365 MICIU/AEI/10.13039/501100011033 Agencia Estatal de Investigación, Unión Europea NextGenerationEU/PRTR; by the Comunidad de Madrid (P2022/BMD-7333 INMUNOVAR-CM); by the Scientific Foundation of the Spanish Association Against Cancer (AECC- PRYGN246642SANC); by the Worldwide Cancer Research WWCR-25-0080; by CRIS Foundation (excellence2025_03); and the by “la Caixa” Foundation (LCF/PR/HR23/52430012 and LCF/PR/HR22/52420019). Work in M.E.’s Laboratory is supported by a seed package from the Icahn School of Medicine at Mount Sinai (Sinai Cloud Fund #IS127201039). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICIU, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MICIU/AEI /10.13039/501100011033)., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2020-001041-S)., Peer reviewed